pro version r1.0, 2017 (treeage software)
90
Structured Review
treeage software
pro version r1.0, 2017
Pro Version R1.0, 2017, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+version+r1%2E0%2C+2017/pro+version+r1+0++2017/pm29209992-79-13-12
Average 90 stars, based on 1 article reviews
Pro Version R1.0, 2017, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+version+r1%2E0%2C+2017/pro+version+r1+0++2017/pm29209992-79-13-12
Average 90 stars, based on 1 article reviews
pro version r1.0, 2017 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Cost Effectiveness of Karyotyping, Chromosomal Microarray Analysis, and Targeted Next-Generation Sequencing of Patients with Unexplained Global Developmental Delay or Intellectual Disability. Article Snippet: Background Genetic diagnosis of unexplained global developmental delay and intellectual disability (GDD/ID) often ends the diagnostic odyssey and can lead to changes in clinical management.. Objective The objective of this study was to investigate the cost effectiveness of testing scenarios involving several methods used to diagnose GDD/ID: karyotyping, chromosomal microarray analysis (CMA), and targeted next-generation sequencing (NGS).. Methods We used decision-tree models to estimate the number of genetic diagnoses, the cost from a payers’ perspective in the USA, and the incremental cost per additional genetic diagnosis. |